59.31
4.08 (7.39%)
| Previous Close | 55.23 |
| Open | 55.66 |
| Volume | 2,507,386 |
| Avg. Volume (3M) | 1,919,854 |
| Market Cap | 5,754,973,696 |
| Price / Earnings (TTM) | 25.35 |
| Price / Earnings (Forward) | 7.07 |
| Price / Sales | 3.36 |
| Price / Book | 3.76 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 |
| Profit Margin | 12.37% |
| Operating Margin (TTM) | 24.56% |
| Diluted EPS (TTM) | 2.34 |
| Quarterly Revenue Growth (YOY) | 65.90% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 87.90% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | -205.79 M |
| Levered Free Cash Flow (TTM) | -445.48 M |
| Return on Assets (TTM) | 3.77% |
| Return on Equity (TTM) | 19.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sarepta Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -4.0 |
| Average | 1.75 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 95.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 183.00 (Needham, 208.55%) | Buy |
| Median | 110.00 (85.47%) | |
| Low | 75.00 (HC Wainwright & Co., 26.45%) | Hold |
| Average | 121.56 (104.96%) | |
| Total | 5 Buy, 4 Hold | |
| Avg. Price @ Call | 63.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 21 Apr 2025 | 110.00 (85.47%) | Buy | 55.23 |
| HC Wainwright & Co. | 16 Apr 2025 | 75.00 (26.45%) | Hold | 53.94 |
| 07 Apr 2025 | 75.00 (26.45%) | Hold | 52.40 | |
| Morgan Stanley | 11 Apr 2025 | 182.00 (206.86%) | Buy | 51.03 |
| Wells Fargo | 11 Apr 2025 | 115.00 (93.90%) | Buy | 51.03 |
| Needham | 03 Apr 2025 | 183.00 (208.55%) | Buy | 58.61 |
| 18 Mar 2025 | 202.00 (240.58%) | Buy | 73.54 | |
| RBC Capital | 31 Mar 2025 | 87.00 (46.69%) | Hold | 63.82 |
| 27 Feb 2025 | 161.00 (171.46%) | Buy | 103.06 | |
| Scotiabank | 20 Mar 2025 | 80.00 (34.88%) | Hold | 73.45 |
| 07 Mar 2025 | 105.00 (77.04%) | Hold | 103.03 | |
| Cantor Fitzgerald | 19 Mar 2025 | 163.00 (174.83%) | Buy | 79.97 |
| 18 Mar 2025 | 163.00 (174.83%) | Buy | 73.54 | |
| Deutsche Bank | 19 Mar 2025 | 99.00 (66.92%) | Hold | 79.97 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |